Literature DB >> 33544204

Reply to: "Hysterectomy versus continuing conservative management: which is better for disseminated intravascular coagulation?"; Shinya Matsuzaki, MD, PhD, Yoshikazu Nagase, MD, Masayuki Endo, MD, PhD, Tadashi Kimura, MD, PhD.

C Biele1, L Kaufner2, A Nonnenmacher1, K von Weizsäcker1, M Z Muallem3, W Henrich1, Thorsten Braun4,5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33544204      PMCID: PMC8840934          DOI: 10.1007/s00404-021-05964-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


× No keyword cloud information.
We would like to thank Matsuzaki S. et al. for reading and valuables comments to our manuscript „Conservative management of abnormally invasive placenta complicated by local hyperfibrinolysis and beginning disseminated intravascular coagulation“ [1]. We support the assumption that severe cases are possible more often treated conservatively (expectant management, EM) and are probably also more often reported in the literature. This is not owed to selection or publication bias, but to the fact that EM is a recommended treatment option especially for severe cases of placenta percreta with organ invasion, when surgical management is considered very high risk as reviewed and recommended recently in the IS-PAS management guidelines [3, 13]. Regarding the incidence of DIC (disseminated intravascular coagulation) in the different groups of placenta accreta spectrum (PAS) during EM, no statement so far can be made, considering that there are only 12 reported cases in the literature [1]. Second, we entirely consent on this point, as our concluding remarks are presented. Therapy for DIC remains unclear, since there are only three reported cases so far [1, 8, 11]. Oral dosage of tranexamic acid might be a promising therapy concept and should be subject of future studies [1, 11]. Third, the authors ask one of the fundamental questions regarding therapy of PAS, whether (cesarean) HE or EM is the better option of treatment, in general and in the case of DIC. The authors suggest three considerations for deciding whether to continue EM or to perform HE in case of DIC: Asymptomatic or symptomatic DIC. According to the authors continuation of EM might only be an option in cases of asymptomatic DIC. Up to now there are three cases of successful treatment of DIC, where HE was not required. In one case the patient was asymptomatic [8], in two cases the patients presented with symptoms (vaginal bleeding, gingival bleeding, easy bruising) [1, 11]. Based on these results we cannot agree with this statement. Expected success rate of conservative management is > 90% after nine weeks of cesarean delivery [7]. The authors conclude this in their review, whereas this applies to all patients, not only those with DIC. Seven patients in the review developed DIC, the median time to occurrence was 67 days after cesarean section (CS), which is 9.5 weeks. Six of the seven patients underwent HE, without information on which day postpartum it was performed. Based on this information we cannot agree with this point either. The severity of PAS. Regarding the letter to the editor, the success rate for EM was higher in non-percreta cases than in percreta cases. On the other hand, the authors recommend HE in non-percreta cases, although it is not clear whether this is a general recommendation or refers to cases with DIC during EM. Further they refer to the high surgical morbidity of HE during EM of placenta percreta. Taking this information into account, it remains unclear whether a severe case of PAS hints for or against the continuation of EM in cases with DIC according to the authors. Regarding EM of PAS in general the authors report a success rate of 61.8% for uterine preservation [7], other available reviews report success rates from 58 to 93% [2, 9, 10, 12, 15]. A retrospective cohort analysis comparing the outcomes of patients having received cesarean HE (n = 20), conservative surgery (placental removal without HE, n = 11) and EM (n = 15) shows a success rate of 93% regarding uterine preservation in the two conservative groups and no significant difference between the two groups. Patients from the EM group experienced significantly lower blood loss and less need for blood transfusion than patients of the other groups [6]. The reported morbidity rate in EM of PAS was 6% [12]. Taking all available data into account, EM might be a safer alternative to cesarean HE in the treatment of PAS. On the other hand, unpredictable and severe complications (infection, hemorrhage, DIC) are possible [14]. The current expert consensus is, that the question of the best therapy option cannot be clarified on the basis of current data and patients should be counselled on both options including the risks. EM seems to be an alternative to cesarean HE especially for patients with unfinished family planning or cases of severe placenta percreta with organ invasion [3, 13]. However, no unified classification of PAS is reported so far in those studies and a direct comparison between studies is difficult. FIGO published in 2019 a new PAS grading classification [4] and recently Eric Jauniaux recommended a histopathological classification of PAS to use [5]. A unified grading system will hopefully help in the future to better compare management strategies and outcomes from centers worldwide and further, high-quality studies are essential to finally clarify this question.
  15 in total

1.  Maternal outcome after conservative treatment of placenta accreta.

Authors:  Loïc Sentilhes; Clémence Ambroselli; Gilles Kayem; Magali Provansal; Hervé Fernandez; Franck Perrotin; Norbert Winer; Fabrice Pierre; Alexandra Benachi; Michel Dreyfus; Estelle Bauville; Dominique Mahieu-Caputo; Loïc Marpeau; Philippe Descamps; François Goffinet; Florence Bretelle
Journal:  Obstet Gynecol       Date:  2010-03       Impact factor: 7.661

Review 2.  FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders.

Authors:  Eric Jauniaux; Diogo Ayres-de-Campos; Jens Langhoff-Roos; Karin A Fox; Sally Collins
Journal:  Int J Gynaecol Obstet       Date:  2019-07       Impact factor: 3.561

3.  Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta.

Authors:  Sally L Collins; Bahrin Alemdar; Heleen J van Beekhuizen; Charline Bertholdt; Thorsten Braun; Pavel Calda; Pierre Delorme; Johannes J Duvekot; Lene Gronbeck; Gilles Kayem; Jens Langhoff-Roos; Louis Marcellin; Pasquale Martinelli; Olivier Morel; Mina Mhallem; Maddalena Morlando; Lone N Noergaard; Andreas Nonnenmacher; Petra Pateisky; Philippe Petit; Marcus J Rijken; Mariola Ropacka-Lesiak; Dietmar Schlembach; Loïc Sentilhes; Vedran Stefanovic; Gita Strindfors; Boris Tutschek; Siri Vangen; Alexander Weichert; Katharina Weizsäcker; Frederic Chantraine
Journal:  Am J Obstet Gynecol       Date:  2019-03-05       Impact factor: 8.661

Review 4.  Conservative management of placenta percreta.

Authors:  Shinya Matsuzaki; Kiyoshi Yoshino; Masayuki Endo; Aiko Kakigano; Tsuyoshi Takiuchi; Tadashi Kimura
Journal:  Int J Gynaecol Obstet       Date:  2018-01-03       Impact factor: 3.561

5.  Leaving the placenta in situ versus conservative and radical surgery in the treatment of placenta accreta spectrum disorders.

Authors:  Mehmet S Kutuk; Mehmet Ak; Mahmut T Ozgun
Journal:  Int J Gynaecol Obstet       Date:  2017-09-18       Impact factor: 3.561

6.  Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta.

Authors:  Lars Schröder; Bernd Pötzsch; Heiko Rühl; Ulrich Gembruch; Waltraut M Merz
Journal:  Obstet Gynecol       Date:  2015-11       Impact factor: 7.661

Review 7.  Management of placenta percreta: a review of published cases.

Authors:  Caroline Clausen; Lars Lönn; Jens Langhoff-Roos
Journal:  Acta Obstet Gynecol Scand       Date:  2013-11-25       Impact factor: 3.636

Review 8.  Conservative management of abnormally invasive placentation.

Authors:  Sarah Timmermans; Arjanneke C van Hof; Johannes J Duvekot
Journal:  Obstet Gynecol Surv       Date:  2007-08       Impact factor: 2.347

Review 9.  Conservative Management of Placenta Accreta Spectrum.

Authors:  Loïc Sentilhes; Gilles Kayem; Robert M Silver
Journal:  Clin Obstet Gynecol       Date:  2018-12       Impact factor: 2.190

Review 10.  Successful anticoagulant therapy for disseminated intravascular coagulation during conservative management of placenta percreta: a case report and literature review.

Authors:  Shinya Matsuzaki; Kiyoshi Yoshino; Masayuki Endo; Takuji Tomimatsu; Tsuyoshi Takiuchi; Kazuya Mimura; Keiichi Kumasawa; Yutaka Ueda; Tadashi Kimura
Journal:  BMC Pregnancy Childbirth       Date:  2017-12-29       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.